Abstract

Cases in which bilateral adrenal 123I-Metaiodobenzylguanidine (123I-MIBG) scintigraphy accumulation is sometimes shown, with mildly elevated catecholamine (CA) or metanephrine (MN) levels (within 3 times the upper reference limit) are diagnostic dilemmas. We experienced 3 cases of adrenal incidentalomas with this dilemma in the differential diagnosis. The clinical diagnosis was subclinical Cushing's syndrome in 2 cases, and primary aldosteronism in 1. Despite suspected CA excess in clinical symptoms and imaging findings, the pathological findings of all these tumors were revealed to be cytochrome P450 family 11 subfamily B member 1 (CYP11B1) positive adrenocortical adenomas. Interestingly, adrenal medullary hyperplasia (AMH) was detected in the adrenal parenchyma of all those backgrounds. To clarify the clinical features of such cases, a cross-sectional study was conducted at the Kobe University Hospital from 2014 to 2020. One-hundred sixty-four patients who had undergone 123I-MIBG scintigraphy were recruited. Among them, 10 patients (6.1%) met the above criteria, including the presented 3 cases. Plasma adrenaline, noradrenaline, urinary metanephrine, and normetanephrine had values of 0.05 ± 0.05 ng/mL, 0.63 ± 0.32 ng/mL, 0.22 ± 0.05 mg/day, and 0.35 ± 0.16 mg/day, respectively. Nine cases were complicated with hypertension, and symptoms related to CA excess were observed. Half of them (5 cases) including presented 3 cases had unilateral adrenal tumors. These suggest that in cases of bilateral adrenal uptake on 123I-MIBG, AMH needs to be considered. Adrenocortical adenomas may be associated with AMH and further larger investigation is needed for this pathology.

Details

Title
Bilateral adrenal uptake of 123I MIBG scintigraphy with mild catecholamine elevation, the diagnostic dilemma, and its characteristics
Author
Inaba, Yuiko 1 ; Yamamoto, Masaaki 2 ; Urai, Shin 3 ; Suzuki, Masaki 3 ; Nishikage, Seiji 3 ; Kanzawa, Maki 4 ; Aoyama, Yayoi 5 ; Kanda, Tomonori 6 ; Shigemura, Katsumi 7 ; Bando, Hironori 8 ; Iguchi, Genzo 9 ; Nakamura, Yasuhiro 10 ; Fujisawa, Masato 11 ; Imagawa, Akihisa 12 ; Fukuoka, Hidenori 2 ; Ogawa, Wataru 3 

 Kobe University Hospital, Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe, Japan (GRID:grid.411102.7) (ISNI:0000 0004 0596 6533); Osaka Medical and Pharmaceutical University, Department of Internal Medicine(I), Takatsuki, Japan (GRID:grid.411102.7) 
 Kobe University Hospital, Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe, Japan (GRID:grid.411102.7) (ISNI:0000 0004 0596 6533) 
 Kobe University Graduate School of Medicine, Division of Diabetes and Endocrinology, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077) 
 Kobe University Hospital, Department of Diagnostic Pathology, Kobe, Japan (GRID:grid.411102.7) (ISNI:0000 0004 0596 6533) 
 Tohoku University Hospital, Department of Pathology, Sendai, Japan (GRID:grid.412757.2) (ISNI:0000 0004 0641 778X) 
 Kobe University Graduate School of Medicine, Department of Radiology, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077) 
 Kobe University Graduate School of Medicine, Division of Urology, Department of Organ Therapeutics, Faculty of Medicine, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077); Kobe University Graduate School of Health Science, Department of Public Health, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077) 
 Kobe University Graduate School of Medicine, Division of Diabetes and Endocrinology, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077); Kobe University Graduate School of Medicine, Division of Development of Advanced Therapy for Metabolic Disease, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077) 
 Kobe University, Medical Center for Student Health, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077); Kobe University Graduate School of Medicine, Department of Biosignal Pathophysiology, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077) 
10  Tohoku Medical and Pharmaceutical University, Division of Pathology, Sendai, Japan (GRID:grid.412755.0) (ISNI:0000 0001 2166 7427) 
11  Kobe University Graduate School of Medicine, Division of Urology, Department of Organ Therapeutics, Faculty of Medicine, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077) 
12  Osaka Medical and Pharmaceutical University, Department of Internal Medicine(I), Takatsuki, Japan (GRID:grid.31432.37) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2672843804
Copyright
© The Author(s) 2022. corrected publication 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.